INVA - Innoviva, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
14.10
+0.01 (+0.07%)
At close: 4:00PM EDT

14.10 0.00 (0.00%)
After hours: 5:24PM EDT

Stock chart is not supported by your current browser
Previous close14.09
Open14.10
Bid7.50 x 3100
Ask15.21 x 2200
Day's range14.01 - 14.33
52-week range11.47 - 17.99
Volume652,849
Avg. volume919,975
Market cap1.431B
Beta1.42
PE ratio (TTM)10.92
EPS (TTM)1.29
Earnings date24 Jul 2018 - 30 Jul 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend date2015-09-08
1y target est15.00
Trade prices are not sourced from all markets
  • Business Wireyesterday

    Innoviva Names Geoffrey Hulme as Interim Principal Executive Officer

    Innoviva, Inc. (INVA) (“Innoviva”) today announced the appointment of Geoffrey Hulme as interim Principal Executive Officer effective May 21, 2018. Mr. Hulme has a 25 year career in finance and investment management with a record of creating and maximizing shareholder value. Prior to joining Innoviva, Mr. Hulme served as the owner and manager of Steel Valley Capital LLC and Steel Valley Advisors LLC, a Registered Investment Adviser.

  • Associated Press27 days ago

    Innoviva: 1Q Earnings Snapshot

    On a per-share basis, the Brisbane, California-based company said it had net income of 27 cents. Earnings, adjusted for amortization costs and non-recurring costs, were 35 cents per share. The biopharmaceutical ...

  • Business Wire27 days ago

    Innoviva Reports First Quarter 2018 Financial Results

    Innoviva, Inc. today reported financial results for the first quarter ended March 31, 2018.

  • Business Wire29 days ago

    Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD

    LONDON & BRISBANE, Calif.--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded ...

  • Business Wire29 days ago

    Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means Trelegy Ellipta can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms. The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.

  • Business Wirelast month

    Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD

    A significant reduction in the risk of on-treatment all-cause mortality was observed for both inhaled corticosteroid containing arms compared to Anoro. Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said, “Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life. The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.

  • Business Wirelast month

    Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD

    Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said, “Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life. The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.

  • Biotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar Ellipta
    Investor's Business Daily2 months ago

    Biotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar Ellipta

    GlaxoSmithKline[ticker symb=GSK] partner Innoviva[ticker symb=INVA] is trying to buck the market correction and finish a new base.  The biotech stock recently received new European Union approval for Relvar Ellipta, an asthma drug Innoviva developed with GSK. Last month, London-based GSK and California-based Innoviva announced that the European Commission approved a label upgrade for Relvar Ellipta. Known as Breo Ellipta in...

  • Business Wire3 months ago

    GSK Announces Positive EU Approval for Labelling Update to Relvar Ellipta in Patients with Asthma

    GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.

  • Business Wire3 months ago

    GSK Announces Positive EU Approval for Labelling Update to Relvar Ellipta in Patients with Asthma

    LONDON & BRISBANE, Calif.--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of ...

  • New Strong Sell Stocks for February 21st
    Zacks3 months ago

    New Strong Sell Stocks for February 21st

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • Business Wire3 months ago

    GSK Submits Landmark IMPACT Data to European Medicines Agency to Support Expanded Label for Trelegy Ellipta

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (for the relief of symptoms and reduction of exacerbations, see section 5.1). Approval of the submission would mean FF/UMEC/VI, the only once-daily single inhalation triple therapy for the treatment of COPD, could be used by physicians to treat a wider population of patients with the condition who are at risk of an exacerbation and require triple therapy.

  • Business Wire3 months ago

    GSK Submits Landmark IMPACT Data to European Medicines Agency to Support Expanded Label for Trelegy Ellipta

    GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease .

  • Why Innoviva Inc. Stock Jumped Tuesday
    Motley Fool3 months ago

    Why Innoviva Inc. Stock Jumped Tuesday

    An activist hedge fund is shaking things up at Innoviva.

  • Associated Press3 months ago

    Innoviva beats Street 4Q forecasts

    The Brisbane, California-based company said it had profit of 45 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...

  • Business Wire3 months ago

    Innoviva Reports Record Fourth Quarter and Full Year 2017 Financial Results

    Innoviva, Inc. today reported financial results for the fourth quarter and full year 2017. Gross royalties earned on net sales of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA® from Glaxo Group Limited during the fourth quarter of 2017 were $70.5 million, up 51% from $46.8 million in the fourth quarter of 2016.

  • Business Wire4 months ago

    Innoviva to Report Fourth Quarter Financial Results on February 8 at 5:00 p.m. EDT

    Innoviva, Inc. announced today that it will report financial results for the fourth quarter and year ended December 31, 2017 after market close on February 8, 2017. Following the earnings release, Innoviva management will host a webcast and conference call at 5:00 p.m.

  • Business Wire4 months ago

    GSK Announces CHMP Positive Opinion for Labelling Update to Relvar Ellipta in Patients with Asthma

    LONDON & BRISBANE, Calif.--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products ...

  • Business Wire4 months ago

    GSK Announces CHMP Positive Opinion for Labelling Update to Relvar Ellipta in Patients with Asthma

    GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting ...

  • Reuters - UK Focus4 months ago

    AstraZeneca's 3-in-1 inhaler helps COPD patients in trial

    AstraZeneca (NYSE: AZN - news) said an inhaler for chronic obstructive pulmonary disease (COPD) delivered improved lung function in a late stage trial that could challenge GlaxoSmithKline (Other OTC: GLAXF - news) 's new three-in-one inhaler. The inhaler, PT010, showed "statistically significant" improvement in eight of nine main lung function goals in patients with moderate to very severe COPD, the company said on Friday.

  • Innoviva Sees RS Rating Rise To 74
    Investor's Business Daily5 months ago

    Innoviva Sees RS Rating Rise To 74

    A Relative Strength Rating upgrade for Innoviva shows improving technical performance. Will it continue?

  • Innoviva Earns Relative Strength Rating Upgrade
    Investor's Business Daily5 months ago

    Innoviva Earns Relative Strength Rating Upgrade

    Innoviva shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

  • Business Wire5 months ago

    Innoviva and Sarissa Implement Court Order

    Innoviva, Inc. today announced it implemented the Delaware Court of Chancery’s order enforcing the oral settlement agreement with Sarissa Capital Domestic Fund LP and certain of its affiliates in connection with the Company’s 2017 annual meeting of stockholders, held on April 20, 2017.

  • Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler
    Zacks6 months ago

    Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler

    Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.

  • Business Wire6 months ago

    GSK Submits Landmark IMPACT Data to US Regulatory Authority to Support Expanded Label for Trelegy Ellipta

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). Approval of this sNDA means FF/UMEC/VI could be used by physicians to treat a wider population of patients with COPD who are at risk of an exacerbation and require triple therapy. It contains an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta2-adrenergic agonist, delivered once daily in GSK’s Ellipta dry powder inhaler, which is used across the entire new portfolio of inhaled COPD medicines.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes